Showing results (101-110 of 231) with videos related to
Sort By:
Pageof 24
Canadian Journal of Veterinary Research = Revue Canadienne De Recherche Veterinaire|August 18, 2020
Prevalence of feline herpesvirus-1, feline calicivirus, <i>Chlamydia felis,</i> and <i>Bordetella bronchiseptica</i> in a population of shelter cats on Prince Edward IslandJulie Walter, Peter Foley, Carmencita Yason, et al.Journal of Drugs in Dermatology : JDD|August 7, 2025
Two-Year Treatment Persistence of Guselkumab vs Other Biologics in Plaque Psoriasis PatientsBruce E Strober, Jud C Janak, Timothy Fitzgerald, et al.The Journal of Dermatological Treatment|January 31, 2020
Dermatologist attitudes toward ciclosporin use in atopic dermatitisKevin Phan, Olivia Charlton, Chris Baker, et al.The Australasian Journal of Dermatology|June 10, 2025
Eight-Year Experience of Hedgehog Pathway Inhibitors at Three Tertiary Referral Centres in the Australian State of VictoriaChristian Gan, Nicholas Manuelpillai, Peter Foley, et al.The Canadian Veterinary Journal = La Revue Veterinaire Canadienne|October 30, 2004
Malignant adrenal neuroblastoma in a young dogLynne Marcotte, Sandra E McConkey, Paul Hanna, et al.The Journal of Investigative Dermatology|October 21, 2011
A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasisKenneth B Gordon, Richard G Langley, Alice B Gottlieb, et al.Cutis|May 16, 2007
Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATEEllen H Frankel, Bruce E Strober, Jeffrey J Crowley, et al.Journal of the American Academy of Dermatology|October 16, 2007
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialAlan Menter, Stephen K Tyring, Kenneth Gordon, et al.Dermatology and Therapy|November 26, 2024
Brodalumab: Six-Year US Pharmacovigilance ReportMark G Lebwohl, John Y Koo, April W Armstrong, et al.Journal of Immunology (Baltimore, Md. : 1950)|November 21, 2007
Specific immunogenicity of heat shock protein gp96 derives from chaperoned antigenic peptides and not from contaminating proteinsRobert J Binder, John B Kelly, Ralph E Vatner, et al.Pageof 24